Impel Pharmaceuticals Revenue and Competitors

Seattle, WA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Impel Pharmaceuticals's estimated annual revenue is currently $17.7M per year.(i)
  • Impel Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Impel Pharmaceuticals has 88 Employees.(i)
  • Impel Pharmaceuticals grew their employee count by -45% last year.

Impel Pharmaceuticals's People

NameTitleEmail/Phone
1
Sr VP Regulatory Affairs, Impel Pharmaceuticals Inc.Reveal Email/Phone
2
SVP, Technical OperationsReveal Email/Phone
3
VP, MarketingReveal Email/Phone
4
VP Pharmaceutical SalesReveal Email/Phone
5
VP, Commercial Operations & AnalyticsReveal Email/Phone
6
VP Human ResourcesReveal Email/Phone
7
Sr. Director, Contracting & TradeReveal Email/Phone
8
Chief Financial OfficerReveal Email/Phone
9
Senior Director, Head Information TechnologyReveal Email/Phone
10
Senior Director, Financial Planning & AnalysisReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15.1M7519%N/AN/A
#2
$0.8M8-50%N/AN/A
#3
$114M5677%N/AN/A
#4
$19.3M9613%N/AN/A
#5
$5.4M2717%N/AN/A
#6
$17.7M88-45%N/AN/A
#7
$13.9M6910%N/AN/A
#8
$5.4M27-10%N/AN/A
#9
$0.8M80%$22MN/A
#10
$5.4M2729%N/AN/A
Add Company

What Is Impel Pharmaceuticals?

Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics.

keywords:N/A

N/A

Total Funding

88

Number of Employees

$17.7M

Revenue (est)

-45%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.8M886%N/A
#2
$22M88-1%N/A
#3
$23.8M886%N/A
#4
$7.5M8811%N/A
#5
$21.6M885%N/A